Baxter International (BAX Quick QuoteBAX - Free Report) reported $2.7 billion in revenue for the quarter ended March 2026, representing a year-over-year increase of 2.9%. EPS of $0.36 for the same period compares to $0.55 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $2.6 billion, representing a surprise of +3.74%. The company delivered an EPS surprise of +15.42%, with the consensus EPS estimate being $0.31.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Baxter performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net Sales- Pharmaceuticals- International: $441 million versus the two-analyst average estimate of $412.19 million. The reported number represents a year-over-year change of +14.3%.
• Geographic Net Sales- United States: $1.44 billion compared to the $1.42 billion average estimate based on two analysts.
• Net Sales- Other- International: $39 million compared to the $29.43 million average estimate based on two analysts. The reported number represents a change of +30% year over year.
• Net Sales- Infusion Therapies and Technologies- International: $455 million compared to the $434.6 million average estimate based on two analysts. The reported number represents a change of +11% year over year.
• Net Sales- Pharmaceuticals: $621 million compared to the $582.11 million average estimate based on four analysts. The reported number represents a change of +6.9% year over year.
• Net Sales- Advanced Surgery: $304 million versus the four-analyst average estimate of $291.29 million. The reported number represents a year-over-year change of +13.4%.
• Net Sales- Other: $90 million versus $80.06 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +15.4% change.
• Net Sales- Front Line Care: $270 million compared to the $282.71 million average estimate based on four analysts. The reported number represents a change of -2.5% year over year.
• Net Sales- Drug Compounding: $320 million versus $274.25 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +30.1% change.
• Net Sales- Care and Connectivity Solutions: $435 million compared to the $439.46 million average estimate based on four analysts. The reported number represents a change of +1.9% year over year.
• Net Sales- Medical Products and Therapies: $1.29 billion versus the four-analyst average estimate of $1.24 billion. The reported number represents a year-over-year change of +1.8%.
• Net Sales- Healthcare Systems and Technologies: $705 million versus $722.17 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +0.1% change.

View all Key Company Metrics for Baxter here>>>

Shares of Baxter have returned +0.7% over the past month versus the Zacks S&P 500 composite's +12.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.